Trial: HVTN 050/Merck 018

IAVI.org

About

Letters

My Account

Trial Details

HVTN 050/Merck 018

Merck 018, STEP

A Worldwide, Phase I, Dose-Escalating Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 gag Vaccine in Healthy Adults

Phase:

Trial Name:

HVTN 050/Merck 018

Study Status:

Terminated

Start Date:

2/11/2003

Product:

MRKAd5 HIV-1 gag

Prime:

MRKAd5 HIV-1 gag

Prime Class:

Viral Vector - Adeno

Organizer, Developer:

HVTN, Merck

Sponsor:

NIAID; Merck

Project Site:

Brazil, Dominican Republic, Haiti, Malawi, Peru, South Africa, Thailand, United States

Number of Volunteers:

435

Principal Investigators:

Dr. Scott Hammer

Web Link:

http://www.hvtn.org

iavireport@iavi.org